Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has
successfully completed patient enrollment in the second of two pivotal
phase 3 trials evaluating the safety and efficacy of two plecanatide
doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation
(CIC). Synergy announced that it had completed patient enrollment in the
first phase 3 CIC trial on January 8, 2015.
for Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks